A specific ALK inhibitor has been shown to exert anti-tumor effects in NSCLC with the EML4-ALK fusion gene.    ///    The tumor specimens were examined by immunohistochemistry for the EML4-ALK fusion gene and by polymerase chain reaction for epidermal growth factor receptor (EGFR) mutations.    ///    The EML4-ALK fusion gene was further detected in 2 cases of undifferentiated cell carcinoma.     ///    "EML4-ALK fusion gene examinations could be more effectively performed by selecting young NSCLC patients without EGFR mutations, whereas selection on the basis of a non-smoking or adenocarcinoma history, as reported in previous studies, may not correctly identify the patient groups with potential EML4-ALK fusion gene.. "    ///    Effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer..     ///    "Between January 2004 and September 2011, the EML4-ALK fusion gene was detected in 19.6% (9/46) of patients. "    ///    "Previous reports suggested an EML4-ALK incidence of approximately 5% in a pan-NSCLC population, with an increased frequency in younger patients, but an appropriate strategy for further selecting patients with the EML4-ALK fusion gene remains unknown. "